Teriflunomide-related development of inverse psoriasis and worsening of pre-existing plaque psoriasis

Kyle Mueller; Susan Pei; Drew Kuraitis

doi:10.5070/D330464111

Teriflunomide-related development of inverse psoriasis and worsening of pre-existing plaque psoriasis

Dermatol Online J. 2024 Aug 15;30(4). doi: 10.5070/D330464111.

Authors

Kyle Mueller, Susan Pei, Drew Kuraitis¹

Affiliation

¹ Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA Department of Dermatology, Tulane University, New Orleans, Louisiana, USA. [email protected].

PMID: 39644471
DOI: 10.5070/D330464111

Abstract

Leflunomide can be used in management of psoriatic disease. Leflunomide's active metabolite, teriflunomide, is used in the treatment of multiple sclerosis and has unexpectedly been rarely reported to induce pustular psoriasis. In this report, we present a patient with multiple sclerosis who developed inverse psoriasis after starting teriflunomide.

Publication types

Case Reports

MeSH terms

Crotonates* / adverse effects
Crotonates* / therapeutic use
Humans
Hydroxybutyrates*
Multiple Sclerosis / drug therapy
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Nitriles* / adverse effects
Nitriles* / therapeutic use
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Toluidines* / adverse effects
Toluidines* / therapeutic use

Substances

Crotonates
Hydroxybutyrates
Nitriles
teriflunomide
Toluidines